Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 8/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635722 | 0.80 | CYP1A2 (0.64) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4863737 | 0.79 | CYP1A2 (1.00) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29704539 | 0.75 | CYP1A2 (0.50) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11353946 | 0.75 | CYP1A2 (0.69) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6011647 | 0.75 | CYP1A2 (0.69) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29457615 | 0.75 | CYP1A2 (0.57) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2935836 | 0.75 | CYP1A2 (0.50) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL549082 | 0.75 | CYP1A2 (0.57) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11228484 | 0.73 | CYP1A2 (0.80) | MAPK1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4921123 | 0.72 | MAOA (0.52) | MAPK1CYP1A2CYP2C9CYP2C19IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111253336-B | Compounds for the treatment of cancer | GTX公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-106794174-B | Compounds for the treatment of cancer | GTX公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3708164-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3139919-B1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10155728-B2 | Compounds for treatment of cancer | GTX INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981915-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| CN-106794174-A | Compounds for the treatment of cancer | GTX公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-3139919-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2015171628-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20070190544-A1 | Methods of screening for resistance to microtuble-targeting drugs | EMORY UNIVERSITY | 2007-08-16 | — | — | US | disclosed |
| US-20050250853-A1 | Beta-tubulin inhibitors | GAUDREAULT RENE C | 2005-11-10 | — | — | US | disclosed |
| US-20020115722-A1 | SS tubulin inhibitors | SOVAR, SOCIETE EN COMMANDITE (CA) | 2002-08-22 | — | — | US | disclosed |
| WO-2001047504-A2 | β-TUBELIN INHIBITORS AND THEIR USE AGAINST CANCER | UNIVERSITé LAVAL (CA) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155728-B2 | Compounds for treatment of cancer | TP53, TUBB1, TUBB6 | MAPK1 3623/4885CYP1A2 4144/4885CYP3A4 3939/4885 |
| US-20180118693-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | MAPK1 3623/4885CYP1A2 4144/4885CYP3A4 3939/4885 |
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | MAPK1 3623/4885CYP1A2 4144/4885CYP3A4 3939/4885 |
| US-20050250853-A1 | Beta-tubulin inhibitors | TUBB, TUBB1, TUBB3 | MAPK1 1500/4885CYP1A2 2835/4885CYP3A4 2978/4885 |
| US-20020115722-A1 | SS tubulin inhibitors | TUBB1, TUBB, TUBB3 | MAPK1 1350/4885CYP1A2 2968/4885CYP3A4 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.